976 related articles for article (PubMed ID: 10639120)
21. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
Volles MJ; Lansbury PT
Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
[TBL] [Abstract][Full Text] [Related]
22. Enhanced oligomerization of the alpha-synuclein mutant by the Cu,Zn-superoxide dismutase and hydrogen peroxide system.
Kang JH; Kim KS
Mol Cells; 2003 Feb; 15(1):87-93. PubMed ID: 12661766
[TBL] [Abstract][Full Text] [Related]
23. Familial Parkinson disease mutations influence α-synuclein assembly.
Ono K; Ikeda T; Takasaki J; Yamada M
Neurobiol Dis; 2011 Sep; 43(3):715-24. PubMed ID: 21684335
[TBL] [Abstract][Full Text] [Related]
24. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
[TBL] [Abstract][Full Text] [Related]
25. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.
Wood SJ; Wypych J; Steavenson S; Louis JC; Citron M; Biere AL
J Biol Chem; 1999 Jul; 274(28):19509-12. PubMed ID: 10391881
[TBL] [Abstract][Full Text] [Related]
26. PA700, the regulatory complex of the 26S proteasome, interferes with alpha-synuclein assembly.
Ghee M; Melki R; Michot N; Mallet J
FEBS J; 2005 Aug; 272(16):4023-33. PubMed ID: 16098186
[TBL] [Abstract][Full Text] [Related]
27. Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant.
Yonetani M; Nonaka T; Masuda M; Inukai Y; Oikawa T; Hisanaga S; Hasegawa M
J Biol Chem; 2009 Mar; 284(12):7940-50. PubMed ID: 19164293
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice.
Casadei N; Pöhler AM; Tomás-Zapico C; Torres-Peraza J; Schwedhelm I; Witz A; Zamolo I; De Heer R; Spruijt B; Noldus LP; Klucken J; Lucas JJ; Kahle PJ; Krüger R; Riess O; Nuber S
Hum Mol Genet; 2014 Feb; 23(3):767-81. PubMed ID: 24064336
[TBL] [Abstract][Full Text] [Related]
29. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states.
Fredenburg RA; Rospigliosi C; Meray RK; Kessler JC; Lashuel HA; Eliezer D; Lansbury PT
Biochemistry; 2007 Jun; 46(24):7107-18. PubMed ID: 17530780
[TBL] [Abstract][Full Text] [Related]
30. Alpha-synuclein structures from fluorescence energy-transfer kinetics: implications for the role of the protein in Parkinson's disease.
Lee JC; Langen R; Hummel PA; Gray HB; Winkler JR
Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16466-71. PubMed ID: 15536128
[TBL] [Abstract][Full Text] [Related]
31. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro.
Cohlberg JA; Li J; Uversky VN; Fink AL
Biochemistry; 2002 Feb; 41(5):1502-11. PubMed ID: 11814343
[TBL] [Abstract][Full Text] [Related]
32. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein.
Bussell R; Eliezer D
Biochemistry; 2004 Apr; 43(16):4810-8. PubMed ID: 15096050
[TBL] [Abstract][Full Text] [Related]
33. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity.
Rekas A; Adda CG; Andrew Aquilina J; Barnham KJ; Sunde M; Galatis D; Williamson NA; Masters CL; Anders RF; Robinson CV; Cappai R; Carver JA
J Mol Biol; 2004 Jul; 340(5):1167-83. PubMed ID: 15236975
[TBL] [Abstract][Full Text] [Related]
34. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
[TBL] [Abstract][Full Text] [Related]
35. Cellular polyamines promote the aggregation of alpha-synuclein.
Antony T; Hoyer W; Cherny D; Heim G; Jovin TM; Subramaniam V
J Biol Chem; 2003 Jan; 278(5):3235-40. PubMed ID: 12435752
[TBL] [Abstract][Full Text] [Related]
36. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.
Jensen PH; Nielsen MS; Jakes R; Dotti CG; Goedert M
J Biol Chem; 1998 Oct; 273(41):26292-4. PubMed ID: 9756856
[TBL] [Abstract][Full Text] [Related]
37. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?
Goldberg MS; Lansbury PT
Nat Cell Biol; 2000 Jul; 2(7):E115-9. PubMed ID: 10878819
[TBL] [Abstract][Full Text] [Related]
38. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein.
Du HN; Tang L; Luo XY; Li HT; Hu J; Zhou JW; Hu HY
Biochemistry; 2003 Jul; 42(29):8870-8. PubMed ID: 12873148
[TBL] [Abstract][Full Text] [Related]
39. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.
Mishizen-Eberz AJ; Guttmann RP; Giasson BI; Day GA; Hodara R; Ischiropoulos H; Lee VM; Trojanowski JQ; Lynch DR
J Neurochem; 2003 Aug; 86(4):836-47. PubMed ID: 12887682
[TBL] [Abstract][Full Text] [Related]
40. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70.
Albani D; Peverelli E; Rametta R; Batelli S; Veschini L; Negro A; Forloni G
FASEB J; 2004 Nov; 18(14):1713-5. PubMed ID: 15345691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
